Table 1 Patient characteristics
From: Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study
| Â | Aggressive lymphoma (n = 36) | High tumor burden indolent lymphoma (n = 12) | Low tumor burden indolent lymphoma (n=27) | P value |
|---|---|---|---|---|
Lymphoma subtype | Â | Â | Â | - |
 DLBCL | 28 (77.8%) | - | - |  |
 AITL | 3 (8.3%) | - | - |  |
 PTCL-NOS | 2 (5.6%) | - | - |  |
 HL | 2 (5.6%) | - | - |  |
 ATLL | 1 (2.8%) | - | - |  |
 FL, grade1, 2, and 3A | - | 6 (50.0%) | 19 (70.4%) |  |
 MZL | - | 6 (50.0%) | 7 (25.9%) |  |
 CLL/SLL | - | 0 | 1 (3.7%) |  |
sMPMTs | Â | Â | Â | Â |
 Localized or advanced |  |  |  | 0.63 |
  Localized | 33 (91.7%) | 10 (83.3%) | 25 (92.6%) |  |
  Advanced | 3 (8.3%) | 2 (16.7%) | 2 (7.4%) |  |
 Cancer type |  |  |  | 0.27 |
  Gastric | 13 (36.1%) | 2 (16.7%) | 9 (33.3%) |  |
  Colorectal | 8 (22.2%) | 6 (50.0%) | 7 (25.9%) |  |
  Lung | 4 (11.1%) | 3 (25.0%) | 1 (3.7%) |  |
  Bladder | 4 (11.1%) | 0 | 1 (3.7%) |  |
  Breast | 1 (2.8%) | 0 | 3 (11.1%) |  |
  Kidney | 3 (8.3%) | 0 | 0 |  |
  Prostatic | 1 (2.8%) | 0 | 1 (3.7%) |  |
  Endometrial | 1 (2.8%) | 0 | 0 |  |
  Esophageal | 1 (2.8%) | 0 | 0 |  |
  Ovarian | 0 | 1 (8.3%) | 0 |  |
  Paranasal | 0 | 0 | 1 (3.7%) |  |
  Pancreatic | 0 | 0 | 1 (3.7%) |  |
  Thyroid | 0 | 0 | 1 (3.7%) |  |
  Thymoma | 0 | 0 | 1 (3.7%) |  |
  Skin cancer | 0 | 0 | 1 (3.7%) |  |